DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 1.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 86,751 shares of the medical device company’s stock after selling 974 shares during the quarter. Retirement Systems of Alabama’s holdings in DexCom were worth $5,816,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in DXCM. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of DexCom during the 2nd quarter worth approximately $25,000. Sachetta LLC boosted its holdings in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares in the last quarter. Riverview Trust Co grew its position in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the period. RPg Family Wealth Advisory LLC purchased a new position in DexCom in the third quarter valued at $57,000. Finally, Covestor Ltd increased its holdings in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after buying an additional 335 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on DXCM shares. Sanford C. Bernstein raised their target price on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Oppenheimer dropped their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Canaccord Genuity Group boosted their price objective on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Stifel Nicolaus increased their target price on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Finally, Leerink Partners cut their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $98.00.

DexCom Stock Down 3.3 %

DXCM stock opened at $75.26 on Thursday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The firm has a 50-day moving average of $74.19 and a two-hundred day moving average of $83.40. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a market cap of $29.40 billion, a price-to-earnings ratio of 45.07, a PEG ratio of 2.46 and a beta of 1.12.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.